	SS	SAPS (N= 132)	Other diagnosis (N= 60)	p
	(N= 77)			
Age (years), mean (SD)	55 (14.3)	55 (14.1)	57 (16.1)	0.8
Gender (women), n (%)	69 (90%)	119 (90%)	53 (88%)	0.45
Sicca syndrome duration (years), mean (SD)	4.9 (5.2)	6 (6.1)	6.7 (6.8)	0.09
Tobacco consomption, n (%)	25 (33%)	49 (37%)	19 (32%)	0.75
Personal history of auto-immune disease, n (%)	15 (20%)	20 (15%)	14 (23%)	0.87
Familial history of auto-immune disease, n (%)	14 (18%)	31 (24%)	10 (17%)	0.7
Use of dry mouth treatment, n (%)	13 (17%)	41 (31%)	20 (33%)	0.02
Body Mass Index (kg/m²), mean (SD)	25.4 (5.7)	24.4 (4.6)	23.7 (4.6)	0.09
Raynaud phenomenon, n (%)	20 (26%)	27 (21%)	13 (22%)	0.45
Arthralgia, n (%)	53 (69%)	102 (77%)	39 (65%)	0.54
Previous history of lymphoma, n (%)	2 (3%)	1 (1%)	0 (0%)	0.41
Parotitis, n (%)	26 (34%)	7 (5%)	12 (20%)	< 0.0001
Objective buccal sicca syndrome*, n (%)	40 (52%)	40 (30%)	19 (32%)	0.002
Objective eye sicca syndrome**, n (%)	61 (79%)	68 (52%)	34 (57%)	< 0.001
ESSPRI, (0-100) mean (SD)	58 (21)	/	/	/
ESSDAI ≥ 5, n (%)	2 (2)	/	/	/
ANA positivity, n (%)	60 (78%)	41 (31%)	26 (43%)	< 0.0001
SSA positivity, n (%)	50 (65%)	4 (3%)	0 (0%)	< 0.0001
SSB positivity, n (%)	20 (26%)	1 (1%)	0 (0%)	< 0.0001
RF positivity, n (%)	26 (34%)	6 (5%)	9 (15%)	< 0.0001
ACPA positivity, n (%)	6 (8%)	1 (1%)	6 (10%)	0.26
C3 (g/L), mean (SD)	1.1 (0.2)	1.1 (0.2)	1.1 (0.3)	0.30
C4 (g/L), mean (SD)	0.2 (0.1)	0.3 (0.2)	0.2 (0.1)	0.009
IgG (g/L), mean (SD)	14.6 (4.7)	10.4 (2.2)	12 (4)	< 0.0001
Chisholm ≥ 3, n (%)	53 (69%)	3 (2%)	1 (2%)	< 0.0001
		3 (2%)	1 (2%)	< 0.0001

Score 0, n (%)	22 (29%)	77 (58%)	31 (52%)	< 0.0001
Score 1, n (%)	16 (21%)	48 (36%)	21 (35%)	0.02
Score 2, n (%)	6 (8%)	6 (5%)	4 (7%)	0.6
Score 3 and 3F, n (%)	33 (43%)	1 (1%)	4 (7%)	< 0.0001

SS, Sjogren's Syndrome

NSDS, Non-Sjogren's Dry Syndrome

ANA, anti-nuclear antibodies

RF, rheumatoid factor

<sup>\*</sup>objectified by unstimulated salivary flow rate test

<sup>\*\*</sup> objectified by Schirmer's test